Real-world overall survival and time to next treatment in patients with metastatic pancreatic ductal adenocarcinoma who received FOLFIRINOX and modified FOLFIRINOX in the first line. This is an ASCO ...
MELBOURNE, Australia, May 29, 2023 /PRNewswire/ -- Amplia Therapeutics Limited (ASX: ATX) ("Amplia" or the "Company") is pleased to announce new data showing the efficacy of its investigational FAK ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback